These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 26945581)

  • 1. Superselective intraarterial cerebral infusion of cetuximab after osmotic blood/brain barrier disruption for recurrent malignant glioma: phase I study.
    Chakraborty S; Filippi CG; Wong T; Ray A; Fralin S; Tsiouris AJ; Praminick B; Demopoulos A; McCrea HJ; Bodhinayake I; Ortiz R; Langer DJ; Boockvar JA
    J Neurooncol; 2016 Jul; 128(3):405-15. PubMed ID: 26945581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Superselective intraarterial cerebral infusion of cetuximab with blood brain barrier disruption combined with Stupp Protocol for newly diagnosed glioblastoma.
    Kulason KO; Schneider JR; Chakraborty S; Filippi CG; Pramanik B; Wong T; Fralin S; Tan K; Ray A; Alter RA; Ortiz R; Demopoulos A; Langer DJ; Boockvar JA
    J Exp Ther Oncol; 2018 May; 12(3):223-229. PubMed ID: 29790314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intraarterial delivery of bevacizumab and cetuximab utilizing blood-brain barrier disruption in children with high-grade glioma and diffuse intrinsic pontine glioma: results of a phase I trial.
    McCrea HJ; Ivanidze J; O'Connor A; Hersh EH; Boockvar JA; Gobin YP; Knopman J; Greenfield JP
    J Neurosurg Pediatr; 2021 Oct; 28(4):371-379. PubMed ID: 34359048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and maximum tolerated dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic blood-brain barrier disruption for recurrent malignant glioma. Clinical article.
    Boockvar JA; Tsiouris AJ; Hofstetter CP; Kovanlikaya I; Fralin S; Kesavabhotla K; Seedial SM; Pannullo SC; Schwartz TH; Stieg P; Zimmerman RD; Knopman J; Scheff RJ; Christos P; Vallabhajosula S; Riina HA
    J Neurosurg; 2011 Mar; 114(3):624-32. PubMed ID: 20964595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Durability of single dose intra-arterial bevacizumab after blood/brain barrier disruption for recurrent glioblastoma.
    Chakraborty S; Filippi CG; Burkhardt JK; Fralin S; Ray A; Wong T; Ortiz R; Langer DJ; Boockvar JA
    J Exp Ther Oncol; 2016 Nov; 11(4):261-267. PubMed ID: 27849336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo assessment of the window of barrier opening after osmotic blood-brain barrier disruption in humans.
    Siegal T; Rubinstein R; Bokstein F; Schwartz A; Lossos A; Shalom E; Chisin R; Gomori JM
    J Neurosurg; 2000 Apr; 92(4):599-605. PubMed ID: 10761648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Superselective intra-arterial cerebral infusion of novel agents after blood-brain disruption for the treatment of recurrent glioblastoma multiforme: a technical case series.
    Shin BJ; Burkhardt JK; Riina HA; Boockvar JA
    Neurosurg Clin N Am; 2012 Apr; 23(2):323-9, ix-x. PubMed ID: 22440875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Intra-arterial chemotherapy of malignant glioma after osmotic blood-brain barrier disruption].
    Yamada K; Takahama H; Nakai O; Takanashi T; Hosoya T
    Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 2):2692-6. PubMed ID: 2506817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rechallenging Recurrent Glioblastoma with Intra-Arterial Bevacizumab with Blood Brain-Barrier Disruption Results in Radiographic Response.
    Faltings L; Kulason KO; Patel NV; Wong T; Fralin S; Li M; Schneider JR; Filippi CG; Langer DJ; Ortiz R; Boockvar JA
    World Neurosurg; 2019 Nov; 131():234-241. PubMed ID: 31351210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Intra-arterial infusion of high dose methotrexate therapy in recurrent gliomas].
    Hayashi A; Kyuma Y
    Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1461-6. PubMed ID: 2117886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A case of recurrent malignant glioma treated by superselective intraarterial chemotherapy with a combination of etoposide and cisplatin].
    Nakagawa H; Kubo S; Fujita T; Tsuruzono K; Miyawaki Y; Arita N; Hayakawa T
    Gan To Kagaku Ryoho; 1992 Feb; 19(2):237-40. PubMed ID: 1736836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Therapeutic efficacy of intracarotid infusion of 20% mannitol with ACNU in Fischer rats with intracerebrally implanted 9L gliosarcoma].
    Miyagami M; Tazoe M; Kasahara E; Tsubokawa T
    Gan To Kagaku Ryoho; 1989 May; 16(5):2059-65. PubMed ID: 2499268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Convection-enhanced delivery of cetuximab conjugated iron-oxide nanoparticles for treatment of spontaneous canine intracranial gliomas.
    Freeman AC; Platt SR; Holmes S; Kent M; Robinson K; Howerth E; Eagleson J; Bouras A; Kaluzova M; Hadjipanayis CG
    J Neurooncol; 2018 May; 137(3):653-663. PubMed ID: 29350351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Superselective intraarterial cerebral infusion of bevacizumab: a revival of interventional neuro-oncology for malignant glioma.
    Riina HA; Fraser JF; Fralin S; Knopman J; Scheff RJ; Boockvar JA
    J Exp Ther Oncol; 2009; 8(2):145-50. PubMed ID: 20192120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of GRN1005 in recurrent malignant glioma.
    Drappatz J; Brenner A; Wong ET; Eichler A; Schiff D; Groves MD; Mikkelsen T; Rosenfeld S; Sarantopoulos J; Meyers CA; Fielding RM; Elian K; Wang X; Lawrence B; Shing M; Kelsey S; Castaigne JP; Wen PY
    Clin Cancer Res; 2013 Mar; 19(6):1567-76. PubMed ID: 23349317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Reversible opening of the blood-brain barrier in the chemotherapy of malignant gliomas].
    Heimberger K; Samec P; Podreka I; Binder H; Suess E; Reisner T; Deecke L; Steger G; Hiesmayr M; Dittrich C
    Wien Klin Wochenschr; 1987 May; 99(11):385-8. PubMed ID: 3113082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Super selective intra-arterial cerebral infusion of modern chemotherapeutics after blood-brain barrier disruption: where are we now, and where we are going.
    D'Amico RS; Khatri D; Reichman N; Patel NV; Wong T; Fralin SR; Li M; Ellis JA; Ortiz R; Langer DJ; Boockvar JA
    J Neurooncol; 2020 Apr; 147(2):261-278. PubMed ID: 32076934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [ACNU delivery to malignant glioma tissue by osmotic blood brain barrier modification with intracarotid infusion of hyperosmoral mannitol].
    Miyagami M; Kagawa Y; Tsubokawa T
    No Shinkei Geka; 1985 Sep; 13(9):955-63. PubMed ID: 2999632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic efficacy of multiagent chemotherapy with drug delivery enhancement by blood-brain barrier modification in glioblastoma.
    Neuwelt EA; Howieson J; Frenkel EP; Specht HD; Weigel R; Buchan CG; Hill SA
    Neurosurgery; 1986 Oct; 19(4):573-82. PubMed ID: 3097567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osmotic blood-brain barrier disruption: pharmacodynamic studies in dogs and a clinical phase I trial in patients with malignant brain tumors.
    Neuwelt EA; Hill SA; Frenkel EP; Diehl JT; Maravilla KR; Vu LH; Clark WK; Rapoport SI; Barnett PA; Lewis SE; Ehle AL; Beyer CW
    Cancer Treat Rep; 1981; 65 Suppl 2():39-43. PubMed ID: 6809316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.